SINPHAR — Interim / Quarterly Report 2021

Nov 11, 2021

==> picture [258 x 100] intentionally omitted <==

==> picture [148 x 100] intentionally omitted <==

==> picture [150 x 100] intentionally omitted <==

==> picture [165 x 100] intentionally omitted <==

SINPHAR PHARMACEUTICAL CO.,LTD Investor Conference

~~Chairman 李志文~~ GM 白友烺& CFO 陳至孝 11 November 2021

==> picture [219 x 88] intentionally omitted <==

==> picture [155 x 87] intentionally omitted <==

==> picture [179 x 87] intentionally omitted <==

1

免責聲明

◼ 本簡報是建立於本公司從各項來源所取得之資 訊。有些資訊可能受未來不確定性因素影響， 致使與原先本公司對於未來前景的說明迥異。 未來若有變更或調整時，請以公開資訊觀測站 公告資訊為依據。

◼ This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there are a variety of factors which could cause actual results to differ materially from those statements. Therefore, please refer to the information on MOPS website as the main basis if any adjustment has been made. (http://mops.twse.com.tw/mops/web/index)

2

Index

1. Instruction 2. Group Operation 3. 2021Q3 Financial Report

4. Important Events 5. Social Responsibility

3

Founded in Taiwan, Step Forward to The World

1977

2002

2012

Established Sinphar Invested Sinphar TianLi, He-Tian Tianli Ilan, Taiwan Hangzhou ( CN )、 Xinjiang(CN ) Generic、functional food、 Generic、TCM、Natural Resources cosmetic

Merged ZuniMed Biotech Nantou,TW Medical facilities

1997

2008

Established CanCap Vancouver, Canada 、 Clinical control for New Drug of North America spot of international business

Co-found SynCoreBio Ilan, Taiwan New Drug Development

==> picture [176 x 93] intentionally omitted <==

==> picture [106 x 93] intentionally omitted <==

==> picture [98 x 93] intentionally omitted <==

==> picture [102 x 93] intentionally omitted <==

==> picture [141 x 93] intentionally omitted <==

==> picture [99 x 93] intentionally omitted <==

4

Group’s Great Health Map

Multi-strength of Generic Drugs

The R&D power of New Drug
Strategic plan of Natural
Herbal Resources

==> picture [233 x 274] intentionally omitted <==

5

Full age and all round protection

==> picture [328 x 348] intentionally omitted <==

----- Start of picture text -----

Vision care Brain care Heart care
Immune Gastrointestinal
Bone health care
regulation care
Allergy
Beauty care Delay aging
regulation
Chronic health Nutritional
Improved sleep
care supplementation
Vitamin.
----- End of picture text -----

==> picture [331 x 351] intentionally omitted <==

----- Start of picture text -----

Dermatology Ophthalmology Pediatrics
Oncology Otolaryngology Orthopedics
Obstetrics &
General Surgery Plastic Surgery
Gynecology
Metabolism Dental Gastroenterology
General
Psychiatry
Medicine
----- End of picture text -----

Listed in 2021：6。

Listed in 2021：2。

6

Sinphar Health Counters

Share relevant medical and health ： knowledge with the public

1.Strengthen direct services
with members. (By 2021, about
46,000 people will join the
membership)

2. Strengthen customer servicerelated after-sales medical and health care knowledge

3. Online sales channels

==> picture [259 x 139] intentionally omitted <==

==> picture [259 x 138] intentionally omitted <==

==> picture [259 x 138] intentionally omitted <==

----- Start of picture text -----

7
----- End of picture text -----

Sinphar Health Park

==> picture [165 x 118] intentionally omitted <==

1.Since the opening of the park, 760
delegations have visited (about 7,300
people in 2021) to understand the
manufacturing process and rigorous
spirit of pharmaceuticals, food and
maintenance products, and nearly 20,000
peopleare expected to visit the factory
in 2022.

==> picture [165 x 100] intentionally omitted <==

==> picture [162 x 100] intentionally omitted <==

2.A free place to exchange health
knowledge for people travelling to Yilan.
To pass on the right knowledge of
medicines and foods and to bring each
other closer together.

==> picture [167 x 100] intentionally omitted <==

S A P

Intelligent manufacturing plant

==> picture [671 x 409] intentionally omitted <==

----- Start of picture text -----

ISO/IEC 27001
◼ Inspection
進貨 IQC 入庫
SA PP
領料
◼ Automatic
sorting
秤料
MES WMS
粉碎
◼ Auto-filter
過篩
混料 ◼ Automatic ◼ Auto-packing ◼ Insspection ◼ Electronic
manufacturing label
充填 合格 合格
檢驗 分裝 貼標 包裝 檢驗 入庫
不合格 不合格
空膠囊
剔除 剔除
ASPROVA
----- End of picture text -----

==> picture [685 x 376] intentionally omitted <==

----- Start of picture text -----

Sustainable Management
Energy Carbon
Saving Reducing
47 % reduction in direct
Average annual power savings
of greenhouse gas emissions
3%
Reduced sludge removal by
approx. 18 %
----- End of picture text -----

Sustainable Management

==> picture [60 x 68] intentionally omitted <==

==> picture [60 x 68] intentionally omitted <==

==> picture [59 x 68] intentionally omitted <==

==> picture [59 x 68] intentionally omitted <==

==> picture [60 x 68] intentionally omitted <==

==> picture [60 x 68] intentionally omitted <==

10

Growth

==> picture [148 x 100] intentionally omitted <==

Therapeutic drug

• New listings are expected in 2022 ： 4 。

• Co-develop and manufacture with Japanese pharmaceutical companies and attack the ASEAN market.

• API in-depth development plan.

Functional Supplements

• New listings are expected in 2022 ： 3 。

• Agent Japanese products into the domestic market.

Cancer treatment drugs

• Actively develop the research and development and manufacturing capacity of cancer needles.

• Product MST (gastric cancer, colorectal cancer, pancreatic cancer) Product A has been certified for listing in 2021.

• Product M (cancer-assisted treatment agent) in the investigation, is expected to serve the country in 2022.

11

Export

Japan：

Product G，Launched in 2020.
Thailand ：

Product T，Launched in 2022.
Product A，Launched in 2024.
Malaysia ：

Product T，Launched in 2020.
Product S，Launched in 2022Q1.
Product K，Launched in 2021.
Philippines ：

Mongolia ：

Product L，Launched in 2020.
Product E，Launched in 2023.
Indonesia ：

Product A，Launched in 2020.
Product B，Launched in 2022Q1.
Vietnam ：

Product G，Launched in 2022.
Iraq ：
Product A，Launched in 2024.

Product L，Launched in 2022.
Product G，Launched in 2022.
Product W，Launched in 2022.

12

Group resources integration

Sinphar & TianLi R&D achievement mutually benefit.

Patents cooperation layout.

==> picture [240 x 240] intentionally omitted <==

----- Start of picture text -----

Oncology
Dosages
----- End of picture text -----

& Sinphar SynCore Drugs in R & D cooperation and manufacturing improve.

Sinphar & ZuniMed ISO15378 Class 100,000 clean room.

13

Sinphar Group's New Drug Catalog

For more information, please
refer to the annual reports.

Memoregain[] Vascular dementia Drug Permit License RMB 55 million Sold

SB03 Veregen® Genital warts Listed in 20 countries

SB05 PC Pancreatic cancer Second-line therapy ： Clinical phase Ⅲ data is under investigation First-line therapy ： Clinical phase Ⅲ NMPA approved and implemented

ST01 ST02 Alzheimer's disease Chronic stable angina US/TW FDA approved ~~US/TW FDA approved~~ Clinical phase Ⅱ Clinical phaseⅡ TW Health Food License Completed SB02 SB01 Cancer drug Head and neck cancer Pre-clinical formulation Clinical phaseⅡ development

SF01 GF159 Cancer adjuvant therapy Brain health food ~~Pre-clinical research~~ Healthy people clinical completed trials completed TW Health Food License SB04 SB05 TNBC Dry age-related macular Triple negative breast degeneration cancer Clinical phaseⅡ/Ⅲ Clinical phase Ⅲ

14

Pipeline of New Products

專注未滿足的醫療 / 市場需求 Focus on Unmet Medical Needs

==> picture [716 x 407] intentionally omitted <==

----- Start of picture text -----

Oncology
Dermatology
Ophthalmology
Ocular
Diagnostic
----- End of picture text -----

15

Development of New Drug

Market value

From Market Research Engine, the global market value of Pancreatic Cancer will increase to US$13 billion in 2021.

According to GLOBOCAN,Pancreatic cancer mortality rate is almost equal to incidence, which is expected to increase by 40% b 2030. y

Market Research Engine Report Id: PPCM417

1. Clinical Studies: Phase III in China ： Received NMPA CTA Approval in June 2019

2. Ongoing Global Phase III Study (Pancreatic Cancer 2nd-Line Therapy After FOLFIRINOX Failure ) ： We were notified on 10/21 that the main indicators of clinical trials were not significant compared to the control group drugs.

16

==> picture [143 x 96] intentionally omitted <==

R&D achievement

2021 America’s Science & Invention Expo 2021 XV International Warsaw Invention Show TianLife SCI papers. patents granted in countries.

year

Achievement

• 2020 3 patents were obtained.

• 4 patents were obtained.

• With the goal of becoming a world-class food 2021 ingredient and selling to the global market. (13 countries)

Target field of Natural Resources

Lipucan®
天力速康®
(Poriacocostriterpenoids)

Protygold®Memoregain® TLCT Plus
杏补宜®天力再生®
(Walnut oligopeptide)(Cistanchetubulosaextracts)

Sleep quality Proven by healthy study population

Sports Nutrition (3 multinational patents )

Boost Respiratory Health (4 multinational patents)

Anti-fatigue Upregulate Immunity & (1 multinational patent) Against Virus infection (2 multinational patents)

Enhance Nutrient Absorption (2 multinational patents)

The application of raw materials in the field of health food tends to be daily life, and the dosage form is not limited to tablets or powders.

18

NTD in Thousand

Recent group revenue

==> picture [620 x 196] intentionally omitted <==

----- Start of picture text -----

2,000,000
1,800,000
1,600,000
1,400,000
療效用藥
1,200,000
1,000,000 功能性食品
800,000
其他
600,000
400,000 合計
200,000
0
2018Q1-Q3 2019Q1-Q3 2020Q1-Q3 2021Q1-Q3
----- End of picture text -----

Term	2018年Q1-Q3	2019年Q1-Q3	2020年Q1-Q3	2021年Q1-Q3	2020
Therapeutic drug	1,112,925	1,180,870	1,243,483	1,157,494	1,585,802
Functional Supplements	449,686	470,993	527,970	563,485	703,165
Others	54,756	71,187	76,509	71,197	99,485
Total	1,617,367	1,723,050	1,847,962	1,792,176	2,388,452

19

NTD in Thousand

Profit and Loss

Sinphar gruop 2021Q1~Q3 2020Q1~Q3 Revenue 1,792,176 1,847,962 Gross Profit 36% 38% S&M -250,076 -239,222 G&A -149,418 -160,773 R&D -418,416 -344,107 Net income (loss) -161,845 -83,336 Net income (loss) attributable to parent -23,099 25,547 company’s shareholders

Syncore Net income (loss)

2021Q1~Q3
-378,462

2020Q1~Q3
-296,260

20

Cash flows

==> picture [288 x 60] intentionally omitted <==

Net Cash generated by operating activities Net Cash used in investing activities Net Cash generated by financing activities Cash and cash equivalents, end of the period

Unspent bank financing

NTD in Thousand

SinpharGruopSyncore
2021Q32021Q3

55,074

-174,379

-123,350

-975

138,222

268,625

1,209,365

632,449

NTD 515,000
RMB  80,000

290,000

21

Ratio

2021Q3 2020Q3 Debt ratio(%) 49.65 49.24 Current ratiob(%) 180.30 187.73 Account receivable turnover 4.96 4.31 Account payable turnover 7.42 7.00 Inventory turnover 2.16 2.45

The increase in inventory was mainly due to the advance stocking in response to the epidemic.

22

2.

3.

4.

2021 events

1. Lipucan® after obtaining 55 patents from 16 countries, the research results were published on the previous day 「Life 2021, 11(2), 111」and 「Life 2021, 11(5), 372 」. Empirical extraction of valuable (Lanostanes) ingredients from the earthen cyst can enhance the body's first line of defense, help to block virus replication and inhibit the life cycle of the virus, and has the ability to regulate the Th1/Th2 response, can reduce the occurrence of allergic asthma.

• The median OS time is 226 days in the GEM+EndoTAG-1 group compared with 209 days in the mono GEM group. The median PFS time is 113 days in the GEM+EndoTAG-1 group compared with 110 days in the mono GEM group.

The combination of Poriacocostriterpenoids and Cistanchetubulosa
extracts,「腦康」Product,wasgranted a patent for the efficacy of "a
composition with memory-improving effect" in China, expanding new areas
and adding intangible assets to the patent layout of apricot-graft raw
materials. (Patent No.: ZL 2018 1 0691573.1)

• Product「蓉易明」lutein compound capsule was awarded the Gold Award at the America’s Science & Invention Expo and the XV International Warsaw Invention Show. the only leafy lutein health product in Taiwan to receive a double gold award.

23

贊助Oxaliplatin予國家衛生研究院執行胰臟癌IIT試驗，以促進國內對於胰臟癌治療之研究

Corporate Social Responsibility

Promote social care, medical prevention and health education

1. Host health forum, biotechnology camp. Combined medical, academia, and biotechnology community to set up an interaction platform. Also, cultivate talented personnel.

2. Continually to sponsor Breast Cancer Foundation, Spinal Cord Injury Foundation, The Diabetes Association of the Republic of China (Taiwan), Taiwan Yilan Association of Diabetes Supporters, and Youngsun Culture & Education Foundation.

3. The donation consortium, the National Health Service and the Taiwan Cancer Foundation, NT$30 million to provide new drug development and Medicaid.

4. Co-found a “ R&D center of Age-related Macular Degeneration” with National Taiwan University -

Hospital, strive for the diagnosis of early stage of age related macular degeneration and eye detection.

1. In long term to protect and maintain street lights at Wanshan village, side walk in Zhongshan village and Renshan trail; also provide a free-use area for trip advisor center in Dongshan County.

2. Donations of nutrition and vegetables to hospitals and epidemic prevention medical personnel in Yilan County amounted to about NTD 1.6 million.

3. Sponsored LuoDong Boai Hospital's biased village consultation and co-sponsored with Taipei Zhongxiao Rotary Club to organize a partial rural breast cancer screening activities.

4. Sponsor Oxaliplatin to the National Institutes of Health to conduct an IIT trial for pancreatic cancer to promote research into the treatment of pancreatic cancer.

24

贊助Oxaliplatin予國家衛生研究院執行胰臟癌IIT試驗，以促進國內對於胰臟癌治療之研究

Corporate Social Responsibility

Support sports and educational activities in long term

1. Sponsor kaohsiung Medical University for a total of 5 million yuan over 5 years, attract talented people and help disadvantaged students to attend school at ease.

2. Sinphar Group and Yilan County Government will jointly organize a three-year ‘Sinphar Yilan Sustainable Urban and Rural Marathon', with a sponsorship of 8 million yuan.

3. Taiwan University Pharmacy Students' Six-Year Student Aid Program and offers internship opportunities during the winter and summer vacations.

4. Provide internship for students from Kaohsiung Medical University, Taipei Medical University, National Defense Medical Center, China Medical University and Chia Nan University of Pharmacy & Science. Also provide scholarship for Kaohsiung Medical University and National Defense Medical Center.

5. Sponsored Yilan High School Football Team and Shun'an Guozhong Baseball Team and Dongshan Township in the local primary school activities sponsored.

6. Set up a 搶孤 cultural park, with a cultural relics room, training ground, heritage folk culture.

7. 110 National First Nations Games, sponsored Yilan County athletes.

25

==> picture [720 x 341] intentionally omitted <==

==> picture [112 x 112] intentionally omitted <==

Q & A

• 合作與開發：張智超。(02-27603688 # 2304)

• 投資人服務：樓怡美。(02-27603688 # 2216)

26